Haematological Malignancy Diagnostic Service

Outreach Coronavirus information

COVID-19 Pandemic

UPDATE JANUARY 2022: Many patients on the HMDS Outreach Service are eligible for a third primary dose and follow-up booster (fourth dose) of the Covid-19 vaccine. For more information and details on how to access this, please click here.

All people monitored by the HMDS Outreach service have a higher risk of COVID-19 illness as a result of their blood disorder. Some people on HMDS Outreach service are extremely vulnerable.

Please check your risk status and relevant guidance for your specific disorder through the links below:

B-lymphoproliferative disorders (includes the following:  “B-cell chronic lymphocytic leukaemia (B-cell CLL)”; “CD5+ LPD –intermediate phenotype”; “CD5-negative B-cell LPD NOS”; “Monoclonal B-cell lymphocytosis (CLL phenotype)”; “MYD88 mutated B-cell lymphoproliferative disorder”; or “Systemic marginal zone lymphoma”)

Monoclonal Gammopathy of Undetermined Significance (MGUS)

If you have an email address, please email leedsth-tr.HMDSOutreach@nhs.net so that we can contact you rapidly if the situation changes. You can also call on 0113 206 7851 and ask to speak to Vicky or Andy but please be aware that call volumes are high at the moment.

Further support may also be available through https://www.myeloma.org.uk (for MGUS patients), https://www.cllsupport.org.uk (for MBL/CLL patients), or https://www.macmillan.org.uk (general advice)